Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
2,505
Views
5
CrossRef citations to date
0
Altmetric
Articles

Re-personalization and stratification of hemophilia care in an evolving treatment landscape

Daniel P. HartThe Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine, QMUL, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9084-8598
ORCID Icon,
Craig M. KesslerDivision of Hematology and Oncology (MedStar), Georgetown University, Washington, DC, USA
&
Lou AledortMount Sinai School of Medicine, New York, NY, USA
Pages 737-741 | Published online: 11 Nov 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

Hemophilia therapeutics are evolving rapidly. Comprehensive care must also evolve to embrace this change. Online tools and guidelines are widely available to optimize prophylaxis with conventional clotting factor concentrates using an individual's predicted pharmacokinetic profile. Novel hemostatic agents (e.g. biphenotypic antibody) are also becoming widely available, with other agents with differing mechanisms of action in final stages of trial. Contemporary issues including challenges of prophylaxis; bleed treatment; laboratory monitoring and inhibitor risk/surveillance are summarized in this narrative review, focusing on how a re-personalization of education and treatment will be necessary to meet these challenges of the rapidly changing therapeutic landscape.

Related Research Data

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
Source: American Society of Hematology
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
Source: Georg Thieme Verlag KG
Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.
Source: Medical Journals Sweden AB
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
Source: Wiley
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement
Source: Wiley
Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study
Source: Wiley
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Source: Massachusetts Medical Society
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
Source: Wiley-Blackwell
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Source: American Society of Hematology
Haemophilia A: mutation type determines risk of inhibitor formation.
Source: Georg Thieme Verlag KG
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
Source: Wiley
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
Source: Wiley
Novel therapeutics for hemophilia and other bleeding disorders
Source: American Society of Hematology
Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A
Source: Wiley
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
Source: Wiley-Blackwell
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
Source: Wiley-Blackwell
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
Source: American Society of Hematology
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Source: New England Journal of Medicine (NEJM/MMS)
Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH
Source: Wiley
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
Source: American Society of Hematology
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Source: American Society of Hematology
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Source: Massachusetts Medical Society
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
Source: Wiley
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
Source: Wiley
PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
Source: Wiley
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Source: New England Journal of Medicine (NEJM/MMS)
The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.
Source: Wiley
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Source: Massachusetts Medical Society

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.